Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD)

Slides:



Advertisements
Similar presentations
Utilization and Outcome of Bone Marrow Transplantation in Children with Sickle Cell Disease: A Pediatric Health Information System Database Analysis 
Advertisements

A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and.
A Pilot Trial of Unrelated Cord Blood Transplantation (UCBT) and Unmatched Human Placental Derived Stem Cells (HPDSC) in Children and Young Adults with.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant  Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,
How to Treat MDS without Stem Cell Transplantation
Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait.
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation Utilizing CD34 Enrichment and T Cell Addback in Children, Adolescents & Adults with.
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
A Pilot Study of Unrelated Cord Blood (UCB) Transplantation and Unmatched Human Placental Derived Stem Cells (HPDSC) in Pediatric Malignant and Non-Malignant.
Biology of Blood and Marrow Transplantation
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
Neuroblastoma and Ewing's Sarcoma Associated with ROR1 Expression Can Be Effectively Targeted with NK Cells Modified to Express an Anti ROR1 Chimeric.
Sabina Kersting, Leo F. Verdonck 
CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.
Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease.
Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation  Bipin N. Savani, Theresa Donohue,
High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.
Recovery of Pulmonary Function after Allogeneic Hematopoietic Cell Transplantation in Children Predicts Improved Survival  Ashok Srinivasan, William Mitchell,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
A Pilot Trial of Unmatched Human Placental Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and.
Safety & Efficacy of Liposomal Amphotericin B Followed By Micafungin to Prevent Invasive Fungal Infection in Pediatric Allogeneic Stem Cell Transplantation.
Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection  Ron Mihelic,
Biology of Blood and Marrow Transplantation
Autologous Stem Cell Transplant in Patients with Primary Central Nervous System Lymphoma: A Multicenter Analysis From the Sarah Cannon Blood Cancer Network 
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+
Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia  Richard Mitchell, Todd Defor, John E. Wagner,
Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies  Robert.
HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease  Anna B. Pawlowska, Jerry C. Cheng,
Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients  Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.
Treatment of High-Risk Sickle Cell Disease (SCD) with Familial Haploidentical (FHI) T- Cell Depleted (TCD) Stem Cell Transplantation with T-Cell Addback.
Potential Use of Human Placenta Derived Stem Cell (HPDSCs) As a Novel Stem Cell Source for the Treatment of Recessive Dystrophic Epidermolysis Bullosa.
ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas  Haein Park, Aradhana Awasthi, Janet Ayello,
Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution!  Anant Vatsayan, MD, Linda.
A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children.
Neurocognitive & Neurological Outcomes in Children, Adolescents & Young Adults with High-Risk SCD Who Have Undergone Familial Haploidentical (FHI) Allosct.
Infection Prevention - Visitors and the Best of Intentions
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA)  Samer.
Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience  Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.
A Successful Approach to Decreasing Central Line Associated Blood Stream Infections  Colleen Butcher, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Carrie.
Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation.
Two Partial T Cell Depletion Strategies for Unrelated Donor Peripheral Stem Cell Transplantation are Associated with Excellent Outcomes for Pediatric.
Steven M. Trifilio, Judy Pi, Jayesh Mehta 
Gerard Socié, K. Scott Baker, Smita Bhatia 
What is quality in a transplant program?
Importance of Site Preparation in Reducing the Risk of Bacterial Contamination during Bone Marrow Harvest  Maheen Z. Abidi, Cassandra Stoll, Anita D'Souza,
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L
Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,
Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.
Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children  Xiaojun.
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation  Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.
Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
A Low Incidence of Nontuberculous Mycobacterial Infections in Pediatric Hematopoietic Stem Cell Transplantation Recipients  Elif Unal, Catherine Yen,
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation  Nikhil Dole, Nathan Luebbering, Nicholas.
Biology of Blood and Marrow Transplantation
Mary Eapen  Biology of Blood and Marrow Transplantation 
Experiences and Decision Making in Hematopoietic Stem Cell Transplant in Sickle Cell Disease: Patients' and Caregivers' Perspectives  Kirshma Khemani,
Presentation transcript:

Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)  Julie-An M. Talano, Cori Abikoff, Carolyn A. Keever-Taylor, Mark C. Walters, Shalini Shenoy, Theodore B. Moore, Susan K. Parsons, Allen J. Dozor, Deborah Friedman, Qiuhu Shi, Suzanne Braniecki, Brenda Grossman, Rona Weinberg, Erin Morris, Phyllis Brand, Sandra Fabricatore, Janet Ayello, Mildred Semidei-Pomales, Lee Ann Baxter-Lowe, Mitchell S. Cairo  Biology of Blood and Marrow Transplantation  Volume 23, Issue 3, Pages S246-S247 (March 2017) DOI: 10.1016/j.bbmt.2016.12.480 Copyright © 2016 Terms and Conditions

Figure 1 (A) Probability of AGVHD: 15 evaluable patients; 7.1% (CI95:0-69.0). (B) Probability of CGVHD 15 evaluable patients; 23.07% (CI95: 1.04-62.4). Biology of Blood and Marrow Transplantation 2017 23, S246-S247DOI: (10.1016/j.bbmt.2016.12.480) Copyright © 2016 Terms and Conditions

Figure 2 Probability 1-year survival n = 18; 87.4% (CI95: 58.1-96.7). Biology of Blood and Marrow Transplantation 2017 23, S246-S247DOI: (10.1016/j.bbmt.2016.12.480) Copyright © 2016 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.